Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
This research study is investigating a new medication called efgartigimod for people with myasthenia gravis who currently rely on IVIG treatment. The main goal is to find out if efgartigimod is as effective as IVIG in managing symptoms and if patients prefer it. Researchers will also be checking how safe efgartigimod is and if people can tolerate it well over six months. Participants will have their usual IVIG stopped one week before starting the new drug. They will then receive regular efgartigimod infusions, with breaks in between, for about 24 weeks. Throughout the study, doctors will monitor how their myasthenia gravis symptoms are changing and their overall quality of life. Other medications for myasthenia gravis will stay the same during the study.
Auf einen Blick
Worum geht es in dieser Studie?
If you have myasthenia gravis, you might be familiar with treatments like IVIG that help manage your condition. This study is exploring a new medication called efgartigimod. The aim is to see if efgartigimod could be a good alternative to IVIG for people whose myasthenia gravis is stable and who need ongoing IVIG treatment.
The main questions this study wants to answer are: Does efgartigimod work as well as IVIG in controlling myasthenia gravis symptoms? Do patients prefer efgartigimod over IVIG? And is efgartigimod safe and easy to take over a six-month period? The study will carefully compare its effects to your current IVIG treatment.
This is an 'open label' study, which means both you and your doctors will know you are receiving efgartigimod. This research is important because it could lead to new ways to treat myasthenia gravis, potentially offering more options for patients in the future.
Wichtige Erkenntnisse
- This study explores a new drug (efgartigimod) for myasthenia gravis.
- It aims to see if efgartigimod can replace IVIG treatment.
- Researchers will compare effectiveness, safety, and patient preference.
- The study lasts 26 weeks, involving regular infusions and breaks.
- Other myasthenia gravis medications will usually remain unchanged.
Wer könnte berechtigt sein?
This study is looking for adults aged between 18 and 80 years old who have myasthenia gravis. To be considered, your myasthenia gravis must be stable, meaning your symptoms and treatment with IVIG haven't changed much in the last four months. You also need to have specific antibodies in your blood (called acetylcholine receptor antibodies) and have been regularly receiving IVIG treatments for at least a year.
There are also some reasons why you might not be able to join. For example, if you've had certain other myasthenia gravis treatments recently (like rituxan or eculizumab). You also can't take part if you've had a specific surgery called a thymectomy in the last three months, or if you have certain active infections like Hepatitis B or C, or untreated tuberculosis.
People who are pregnant or planning to get pregnant in the next six months cannot participate. Those with severe kidney problems or very low levels of a certain antibody (IgG) in their blood will also be excluded. Ultimately, your doctor will decide if this study is suitable for you.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie zwischen 18 und 80 Jahre alt?
- Has your myasthenia gravis been stable for at least 4 months?
- Have you been regularly receiving IVIG for over a year?
- Are you able to commit to weekly assessments and infusions for part of the study?
- Are you not pregnant or planning to become so within 6 months?
Was beinhaltet die Teilnahme?
If you join this study, your current IVIG treatment will be stopped one week before the study officially starts. Other medications you take for myasthenia gravis, such as non-steroid immunosuppressant therapies, acetylcholinesterase inhibitors, or corticosteroids, will stay the same throughout the study.
You will receive efgartigimod as an infusion into a vein, given at a hospital or clinic. This will happen once a week for four weeks. After these four infusions, you'll have a four-week break from the medication. This cycle of four weeks of infusions followed by a four-week break will repeat four times in total, lasting about 24 weeks. After the last treatment, there will be a two-week observation period, with a final visit at week 26.
Throughout the study, you will have weekly checks to assess your myasthenia gravis symptoms and how they affect your daily life. This helps the doctors understand how well the new medication is working for you. So, expect regular visits and assessments over the 26-week period.
Potenzielle Risiken und Vorteile
Standorte (1)
- Clinique Neuro-OutaouaisVerifizierte PostleitzahlGatineau, Canada· Rekrutierung
Häufige Fragen
Was ist Myasthenia gravis?
Myasthenia gravis is a long-term condition that causes muscle weakness. It can affect muscles in the eyes, face, throat, and limbs.
What is IVIG?
IVIG stands for Intravenous Immunoglobulin. It's a treatment given into a vein that uses antibodies from healthy donors to help calm the immune system.
What is 'stable disease'?
Stable disease means your myasthenia gravis symptoms haven't significantly worsened or changed, and your IVIG treatment frequency and dose have been consistent for a while.
Will I have to stop all my other myasthenia gravis medications?
No, you will only stop your IVIG. Other medications you take for myasthenia gravis will stay the same during the study.
Wie lange werde ich an der Studie teilnehmen?
The study will last for a total of 26 weeks, which is about six months.
Wie Sie mehr erfahren können
François Jacques, Doctor
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.